Morphic Holding (MORF) Osake Kurssi
Morphic Holding Kurssi
Morphic Holdingn liikevaihto on supistunut 31,1 % vuodessa viimeisten 5 vuoden aikana 521 000,00 USD:een. Morphic Holdingn nettomarginaali −29 192,9 % on laskenut verrattuna −255,2 %:iin muutama vuosi sitten. Morphic Holdingn 12 kuukauden konsensustavoitehinta on 58,14 USD, noin yli kurssia 2,0 %. 15 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Pidä.
Morphic Holding osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Morphic Holding liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Morphic Holding -osakkeesta
The business model of Morphic Holding Inc is focused on discovering and developing oral small molecule integrin therapeutics. These therapeutics aim to treat chronic diseases by selectively targeting integrins, which are proteins involved in cell adhesion and signaling. Morphic Holding Inc's proprietary Morphic Integrin Therapeutics (MIT) platform enables the design of integrin-targeting drug candidates with improved selectivity, efficacy, and safety profiles. By leveraging their expertise in drug discovery and integrin biology, Morphic Holding Inc strives to advance potential treatments for conditions such as autoimmune diseases, fibrosis, and cancers.
Morphic Holding Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Morphic Holding Inc in the market include pharmaceutical companies such as Biogen Inc, Amgen Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the biotechnology industry and focus on developing innovative therapies and drugs for various conditions. By being aware of the competitive landscape, investors and individuals interested in Morphic Holding Inc can gain insights into the market dynamics and potential challenges the company may face.
Morphic Holding Inc is a reputable company specializing in the field of biotechnology. Founded in 2014, Morphic focuses on developing integrin-targeted therapeutics for chronic inflammatory and autoimmune diseases. The company boasts a talented team of scientists and researchers dedicated to advancing new treatment options. Morphic has collaborated with several renowned institutions and pharmaceutical companies to develop novel drugs targeting specific integrins, thus making significant strides in the field of biopharmaceuticals. With their rich history and strong track record, Morphic Holding Inc continues to make promising advancements in the biotechnology industry, showcasing their commitment to improving global healthcare.
Morphic Holding Inc has achieved significant milestones since its establishment. The company successfully completed its initial public offering (IPO) and listed on the Nasdaq stock exchange under the ticker symbol MORF. Moreover, Morphic Holding Inc has made notable advancements in its drug discovery research and development programs, particularly in the field of integrin-targeted therapies. This has allowed the company to progress multiple drug candidates into various stages of clinical trials, highlighting its dedication to addressing unmet medical needs. Morphic Holding Inc continues to strive for excellence in the pharmaceutical industry, constantly pushing boundaries to bring innovative treatments to patients worldwide.
Morphic Holding Inc is primarily present in the United States.
Morphic Holding Inc represents a set of core values and corporate philosophies that drive their operations. With a focus on innovation, they are committed to pushing boundaries and delivering groundbreaking solutions in the biopharmaceutical industry. As a company, Morphic Holding Inc values integrity, transparency, and ethical practices, ensuring they uphold the highest standards in all their endeavors. By fostering a collaborative environment, they encourage teamwork, diverse perspectives, and a shared passion for making a positive impact on patients' lives. Morphic Holding Inc's dedication to excellence and patient-centric approach defines their identity and drives their pursuit of pioneering therapeutic advancements.
Analyytikot asettavat tällä hetkellä Morphic Holding-osakkeelle keskimääräisen tavoitehinnan 59,60 USD (mediaani: 58,14 USD), mikä merkitsee +4,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 15 analyytikkoarvioon.
15 analyytikkoa arvioi tällä hetkellä Morphic Holding-osaketta: 7 suosittaa ostoa, 8 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Morphic Holding-yhtiöltä 408 000,00 USD liikevaihtoa ja −5,40 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Morphic Holding-osake noteerataan hintaan 50,74 EUR (56,99 USD).
Morphic Holding-osake (MORF) on listattuna 4 pörssissä, muun muassa: NASDAQ (MORF), Frankfurt (31Y.F), München (31Y.MU), Düsseldorf (31Y.DU).
Morphic Holding Inc is a US-based biotechnology company focused on the discovery and development of drugs based on the science of integrin pharmacology. The company was founded in 2015 and is listed on the Nasdaq stock exchange under the symbol "MORF". This article will describe the business model of Morphic Holding Inc. Integrin pharmacology is a novel therapeutic strategy that specifically targets integrins to modulate specific cell/tissue interactions. Integrins are protein molecules on the surface of cells that are responsible for cell adhesion, cell migration, and signal transduction, making them important targets for drug development. Morphic Holding Inc has a strong portfolio of proprietary molecules that modulate integrins to treat diseases such as inflammatory bowel disease, fibrosis, cancer, pain, and autoimmune diseases. The company also has strategic partnerships with leading pharmaceutical companies such as AbbVie, Janssen, and Schrödinger to further intensify their research. Morphic's business model involves developing innovative drugs based on integrin pharmacology and licensing them to pharmaceutical companies. The company pursues a dual strategy by independently advancing its own pipeline while also demonstrating the value of its technology platform through collaborations. Morphic's product portfolio includes several drugs in development targeting fibrosis, inflammatory bowel disease, cancer, and autoimmune diseases. The lead product candidate, MORF-057, is a selective integrin α4β7 antagonist developed for the treatment of inflammatory bowel disease and is currently in Phase 2 clinical trials. Furthermore, the company recently completed the acquisition of Morphic Therapeutic Europe Limited, a company focused on researching and developing integrin-mediated tumor metastasis blockade. This acquisition expands Morphic's portfolio with innovative preclinical drug candidates for the treatment of cancer based on integrins. In summary, Morphic Holding Inc has an innovative business model based on integrin pharmacology. The company develops drugs targeting a variety of diseases by specifically modulating integrins. Their products are currently in development and have the potential to achieve significant therapeutic advancements. Through strategic partnerships and acquisitions, the company is further expanding its position in the biotechnology sector.
odotettu liikevaihto Morphic Holding on 408 000,00 USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Morphic Holding on −226,92 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Morphic Holding:n hinta-voitto-suhde (P/E) on tällä hetkellä −10,55. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Morphic Holding-osakkeen arvostusta.
Morphic Holding:n hinta-myynti-suhde (P/S) on tällä hetkellä 5 866,62. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Morphic Holding-osakkeen arvostuskennuslukuna.
Morphic Holding:n Eulpool-laatuscore on 2/10.
Morphic Holding:n ISIN on US61775R1059. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Morphic Holding:n WKN on A2PLX9. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Morphic Holding:n ticker on MORF. Tämä pörssinoteeraus käytetään Morphic Holding-osakkeiden kauppaan pörssissä.
Morphic Holding osake
Morphic Holding vertaisryhmä
Morphic Holding Ticker
Morphic Holding FIGI
Kaikki tunnusluvut ja syvällinen analyysi Morphic Holding:sta
Meidän osakeanalyysimme Morphic Holding-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Morphic Holding:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: